US SMID Cap Biotech: M&A back on track, with a more structural sector recovery

Overview

This report is the 65th edition of Morgan Stanley's Finger On The Pulse US SMID Cap Biotech series, themed More M&A, back on track for a record year. It covers the US SMID Cap Biotech sector and discusses M&A, capital markets, cash runways, divergences in 13F holdings, interest rates and valuation, negative enterprise value screening, frontline innovation catalysts in 2026, and changes in FDA regulation.

Core views

The core views are: first, biopharma M&A demand is more structural than cyclical, as large pharma companies face patent expirations and revenue gaps and need to replenish external pipelines; second, stable to declining interest rates will ease discounting pressure on long-duration biotech cash flows and improve risk appetite; third, opportunities within the sector are more selective, with capital favoring later-stage, de-risked, or clearly catalyzed assets; fourth, negative enterprise value companies and frontline innovation programs provide upside optionality, but cash runway, regulation, and clinical outcomes still determine divergence.

Analysis framework

The report uses a multidimensional sector monitoring approach: it tracks M&A and capital markets transactions, assesses cash runways of pre-commercial companies, compares 13F holding changes between hedge funds and mutual funds, builds a four-bucket segmentation for commercial-stage companies based on growth and product dependence, analyzes valuation in conjunction with interest-rate trends, screens for low to negative enterprise value companies, and follows clinical, regulatory, and FDA accelerated approval-related catalysts.

Methodology notes

• 行业供需框架生物制药并购结构性需求框架

  Large pharma patent expirations and external pipeline replenishment

  The report argues that M&A demand is influenced not only by interest rates, but also by the patent expiry and revenue replacement pressure that large biopharma companies face toward the end of this decade, making SMID Cap Biotech assets potential ongoing M&A targets.

• 财务韧性评估现金跑道估算

  Using cash balances and operating cash burn to measure financing buffer

  Cash runway is derived from company guidance, Morgan Stanley models, or calculation-based methods; the calculation method mainly uses 3Q25 cash divided by FY24 operating cash burn, with cash balances based on the latest disclosed data.

• 资金行为分析13F持仓分歧框架

  Comparing holding changes between hedge funds and mutual funds across different time windows

  The report uses 3-month, 6-month, and 12-month holding changes to identify risk appetite, turnaround-asset buying, high-consensus longs, shared reductions, and event-driven trading.

• 公司分层框架四镜头商业化覆盖框架

  Segmenting commercial-stage SMID Cap Biotech by growth source and rising risk order

  Lens 1 includes balanced-growth companies, Lens 2 includes companies driven by a single marketed product, Lens 3 includes pipeline-dependent growth companies, and Lens 4 includes slower-growth companies; risk increases from Lens 1 to Lens 4.

• 估值筛选负企业价值筛选

  Looking for biotech companies whose market capitalization is below cash, with negative EV or near-negative EV

  The report uses low to negative enterprise value to identify extreme undervaluation or asset-value mismatches, while also noting that such companies are often accompanied by financing, R&D failure, or uncertainty around the commercialization path.

• 事件与监管跟踪临床催化剂与FDA加速批准跟踪

  Tracking clinical data, regulatory decisions, accelerated approvals, and confirmatory trial requirements

  The report believes that clinical and regulatory events have recently had sharper impacts on stock prices, and that accelerated approval policy and confirmatory trial requirements affect the timelines and risk-reward profiles of related companies.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• US SMID Cap Biotech equity portfolio

  The core subject of the report, representing small- and mid-cap biotech equity assets

  Strengths

  Valuations are at low levels, M&A demand is structurally strengthening, expected rate declines improve valuations for long-duration assets, and clinical and regulatory catalysts are dense.

  Weaknesses

  High dependence on financing, sharp stock-price volatility from clinical failures and regulatory delays, and weaker commercialization visibility than large pharma.

  Comparison

  Compared with large biopharma, these companies are smaller, higher beta, and offer greater M&A elasticity; compared with mature healthcare stocks, they are more affected by rates and risk appetite.

  Risks

  Persistently high rates, closure of the financing window, tighter FDA policy, clinical data missing expectations, and antitrust or execution risks in M&A.

• Negative enterprise value biotech basket

  A screening set for valuation mismatch and potential rebound

  Strengths

  Trading below cash, theoretically offering asset-value protection and M&A optionality; the report shows total cash is significantly higher than total market cap.

  Weaknesses

  Low valuation may reflect issues in pipeline quality, cash burn rate, or strategic outlook, and does not automatically represent a margin of safety.

  Comparison

  Cheaper in valuation than positive enterprise value companies, but also typically represents higher financing and pipeline risk.

  Risks

  Rapid cash burn, pipeline failure, dilution from equity financing, delisting, or constrained strategic options.

• Commercial-stage balanced-growth companies (ALNY, ARQT, BBIO, INSM, NBIX, ONC, etc.)

  The relatively lower-risk commercial coverage group in the four-lens framework

  Strengths

  Less dependent on a single product and unlaunched pipelines, with a clearer revenue base, making them more likely to attract capital preference when rates are high or risk appetite is weak.

  Weaknesses

  If growth is fully priced by the market, upside elasticity may be lower than that of earlier-stage or pipeline-dependent companies.

  Comparison

  Compared with pipeline-dependent companies, they have stronger cash flow and commercialization visibility; compared with large pharma, they still offer higher growth elasticity.

  Risks

  Slower commercialization growth, intensifying competition, rising product concentration, and valuation compression.

• Pipeline-dependent or pre-commercial companies (ARWR, AXSM, DNLI, EXEL, IONS, MIRM, PTCT, RARE, etc.)

  Higher-risk innovation assets with greater catalyst elasticity

  Strengths

  Share-price elasticity is high when new products or new mechanisms succeed, benefiting from improving risk appetite and M&A demand.

  Weaknesses

  Growth is highly dependent on products not yet launched or not yet validated, making cash burn and financing needs more prominent.

  Comparison

  Compared with commercial balanced-growth companies, upside is higher but so are failure probability and volatility.

  Risks

  Clinical data failure, regulatory delay, financing dilution, and catalysts being reflected in the stock price ahead of time.

• Large biopharma buyers (LLY, J&J, GSK, etc.)

  Source of M&A demand for SMID Cap Biotech

  Strengths

  Stronger cash flow and motivation to replenish pipelines and revenue through acquisitions when facing patent-expiry pressure.

  Weaknesses

  Large deals require taking on integration, regulatory approval, and overvaluation risks.

  Comparison

  Compared with SMID Cap Biotech, large pharma acts more as an acquirer and capital provider rather than a high-beta innovation asset.

  Risks

  Deal failure, delayed regulatory approval, weaker-than-expected integration, and acquired assets underperforming in clinical or commercial execution.

Key data

• 2026 M&A volume and value30 deals, totaling about $86 billionAs of the report date, announced biopharma M&A in 2026 was close to a record-year pace.
• 2025 M&A comparison40 deals, totaling about $110 billionThe report uses 2025 as a comparison to show that M&A activity in 2026 remains elevated.
• LLY M&A shareMore than 33% of 2026 M&A deal countLLY is clearly ahead of other companies in 2026 biopharma M&A.
• GSK/Nuvalent deal$10.6 billionAnnounced on June 9, 2026, it was the largest deal since February 2026.
• Large pharma LOE pressureAbout $150 billion by 2030The value pressure from patent expirations faced by large biopharma companies is an important source of M&A demand for SMID Cap Biotech.
• Cash runway of pre-commercial companiesAbout 50% over 2 years; 22/50 at 1 to 2 years; 4/50 under 1 yearDivergence in cash buffers means some companies may still need to raise capital sooner.
• Interest-rate assumptionFed policy rate stays at 3.5% to 3.75%; the MS economics team expects one rate cut each in January and March 2027The expected terminal target range is 3.0% to 3.25%, and falling rates would help lift valuations for long-duration biotech.
• Summary of negative enterprise value companiesTotal market cap about $3.4 billion, total cash about $5.8 billionEquivalent to about a 39.0% discount to cash, showing that some companies are near historically low valuations.
• Examples of capital divergenceHedge funds increased positions while mutual funds reduced positions in AXSM, BBIO, and BMRNHedge funds are more oriented toward taking risk and pursuing alpha, while mutual funds focus more on drawdowns and liquidity.
• Examples of mutual fund turnaround buyingVKTX, ZNTL, CRVSMutual funds increased long-term optionality in some pressured or speculative assets.
• Examples of high-consensus longsKYTX, ABSI, IVVD, NRIXThese names are representative innovation beta exposures with notably shared accumulation by both hedge funds and mutual funds.
• FDA accelerated approval requirementsMust meet safety and efficacy standards and usually require post-marketing confirmatory studiesNew FDA guidance emphasizes product withdrawal and confirmatory trial progress, affecting the pricing of regulatory risk.

Impact & implications

The investment implication is that US SMID Cap Biotech may be entering a recovery phase with stronger fundamental support, but opportunities will not spread evenly. Falling rates and M&A will improve sector risk appetite, and companies with ample cash, later-stage pipelines, frontline innovative mechanisms, or strategic appeal to large pharma acquirers are more likely to benefit; companies with insufficient cash runway, uncertain regulatory timelines, or clinical catalysts already priced in may remain under pressure.

Risks

• If rates remain high or rate cuts are delayed, valuations and risk appetite for long-duration biotech may come under pressure again.
• FDA regulatory policy, accelerated approval requirements, and confirmatory trial timelines may alter product launch schedules.
• Clinical data and regulatory events are binary in nature, and some stocks may experience significant volatility after catalysts.
• Companies with insufficient cash runway may need to raise capital sooner, leading to dilution or financial pressure.
• If M&A expectations do not materialize, undervalued and negative enterprise value names may continue to trade at discounts.
• Crowded high-consensus 13F trades may amplify short-term drawdowns, especially in less liquid small- and mid-cap stocks.
• Morgan Stanley discloses that it served as financial advisor in several related transactions, and investors should note potential conflicts of interest.

What to watch

• The number, individual deal size, and participation of large biopharma companies in subsequent biopharma M&A during 2026.
• Whether the Fed's rate-cut path matches the MS economics team's expectation of cuts in January and March 2027.
• Whether pre-commercial companies with less than 1 year of cash runway initiate financing, partnerships, or strategic transactions.
• Whether hedge funds and mutual funds continue to diverge in 13F positioning, or shift toward jointly increasing later-stage de-risked assets.
• Whether the number of negative enterprise value companies and the magnitude of discounts continue to decline.
• Whether 2026 clinical data and regulatory catalysts for frontline innovation programs are delivered.
• Whether FDA accelerated approval, confirmatory trial, and product withdrawal policies tighten further.
• Whether large biopharma companies such as LLY, J&J, and GSK continue to replenish pipelines through acquisitions.